Site Search

Search
Showing 1 - 7 of 7 results
About the CF Foundation | CFTR Modulators | Genetic Therapies
The Cystic Fibrosis Foundation Applauds FDA Approval of Kalydeco™, First Drug to Address the Underlying Cause of Cystic Fibrosis

Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model

Press Release |
| 5 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
Cystic Fibrosis Foundation Applauds Successful Phase 3 Results of Ivacaftor (Kalydeco™) and Lumacaftor (VX-809) Drug Combination for People with Two Copies of F508del Mutation of Cystic Fibrosis

CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process

Press Release |
| 5 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
Cystic Fibrosis Foundation Issues Statement on The New England Journal of Medicine Study on the Benefits of the Ivacaftor/Lumacaftor Combination Drug
Press Release |
| 3 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
CF Foundation Celebrates FDA Approval of Orkambi as Important Advance for the CF Community

Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation

Press Release |
| 5 min read
Research | CFTR Modulators | Drug Pipeline
Cystic Fibrosis Foundation statement on FDA approval of TRIKAFTA, the first triple combination therapy for the most common CF mutation

This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.  

Press Release |
| 3 min read
About the CF Foundation | CFTR Modulators | Research
FDA Approves Ivacaftor for Children Ages 2 to 5 with Certain Rare CF Mutations
Press Release |
| 3 min read